Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

17 Dec 2025 07:00

RNS Number : 8228L
Bunzl PLC
17 December 2025
 

17 December 2025

BUNZL PRE-CLOSE STATEMENT

2025 PROFIT IN-LINE WITH EXPECTATIONS

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the year ending 31 December 2025.

 

Despite the ongoing macro economic challenges in our key end markets, we reiterate the 2025 adjusted operating profit guidance we first set out within our Q1 trading update. Group revenue in 2025 is expected to grow between 2% and 3%, at constant exchange rates, and to be broadly flat at actual exchange rates. Group revenue growth at constant exchange rates is expected to be driven by acquisitions, with broadly flat underlying revenue over the year. Despite the tougher comparatives, we expect to see good momentum over the final quarter, supported by the benefits of actions taken to improve our performance, including new business wins in North America. Group adjusted operating profit is expected to be in-line with expectations, with operating margin around 7.6%. We expect to demonstrate a moderation of the Group's year-on-year operating margin decline in the second half compared to the first half of the year, driven by: the benefit of actions taken in North America and Continental Europe to improve performance; easier comparatives in Continental Europe; and Nisbets synergy benefits.

 

Looking ahead into 2026, uncertainties relating to the wider economic and geopolitical landscape are expected to continue. The Group expects moderate revenue growth in 2026, at constant exchange rates, driven by some underlying revenue growth and a small benefit from announced acquisitions. Group operating margin is expected to be slightly down year-on-year.

 

In October, Bunzl completed the acquisition of Damito s.r.o, a distributor of cleaning & hygiene, personal protective equipment and packaging in Slovakia. The acquisition establishes Bunzl's physical presence in Slovakia, and the business generated revenue of EUR 14 million (c.£12 million) in 2024. We have also completed our £200 million 2025 buyback and continue to expect leverage to be just over, and towards, 2.0 times at the end of 2025.

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Despite what has remained a challenging market, we expect to meet our outlook for 2025, which was set out in April this year. We continue to remain strongly focused on performance across the Group and are encouraged by operational improvements being made and new business wins in North America. We have presented our view of 2026 which highlights our expectations for a return to organic growth and ongoing cost actions to support a more stable profit outlook.

 

We also welcome Damito to the Bunzl family, with the Slovakian business expanding our offering to customers. After a lower level of acquisition spend in 2025, reflective of timing and driven by macro economic uncertainty, and with our pipeline remaining active, we look forward to an improved year for acquisitions in 2026.

 

We remain confident in the Group's underlying resilience and strength, and ability to deliver consistent compounding growth in the medium-term."

 

Conference call

There will be a live analyst and investor conference call and Q&A session from 07:30am (GMT) today, hosted by Richard Howes (Chief Financial Officer). A replay will be available later in the day.

· Dial-in number: +44 20 3936 2999 / Access code: 945151

 

 

Enquiries:

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

 

Teneo

Martin Robinson

Kate Somerville

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLBDDRXBDGUL
Date   Source Headline
18th Apr 20248:00 amRNSAdditional Listing
11th Apr 20248:00 amRNSAdditional Listing
3rd Apr 20245:28 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:09 amRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
21st Mar 20248:00 amRNSAdditional Listing
15th Mar 20243:28 pmRNSAnnual Financial Report
7th Mar 20248:00 amRNSAdditional Listing
5th Mar 20245:05 pmRNSDirector/PDMR Shareholding
4th Mar 20243:03 pmRNSDirector/PDMR Shareholding
1st Mar 202411:35 amRNSTotal Voting Rights
28th Feb 20243:17 pmRNSDirector/PDMR Shareholding
27th Feb 20245:26 pmRNSDirector/PDMR Shareholding
26th Feb 202410:30 amRNSDividend Declaration
26th Feb 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSAcquisition
5th Feb 20242:20 pmRNSDirector/PDMR Shareholding
1st Feb 20245:08 pmRNSTotal Voting Rights
12th Jan 20244:54 pmRNSDirector/PDMR Shareholding
11th Jan 20243:50 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:57 amRNSTotal Voting Rights
15th Dec 20235:10 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSTrading Statement
8th Dec 20235:32 pmRNSDirector/PDMR Shareholding
1st Dec 202311:32 amRNSTotal Voting Rights
20th Nov 20236:30 pmRNSPublication of Admission Particulars
3rd Nov 20239:30 amRNSDirector Declaration
2nd Nov 20232:29 pmRNSDirector/PDMR Shareholding
1st Nov 202311:24 amRNSTotal Voting Rights
1st Nov 20239:00 amRNSBlock listing Interim Review
24th Oct 20237:00 amRNSTrading Statement
6th Oct 20235:08 pmRNSDirector/PDMR Shareholding
4th Oct 20231:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:34 pmRNSTotal Voting Rights
2nd Oct 20231:33 pmRNSDirector/PDMR Shareholding
26th Sep 20232:10 pmRNSDirector/PDMR Shareholding
1st Sep 20232:30 pmRNSTotal Voting Rights
31st Aug 202310:30 amRNSDirector/PDMR Shareholding
29th Aug 202310:00 amRNSDividend Declaration
29th Aug 20237:00 amRNSHalf-year Report
29th Aug 20237:00 amRNSAcquisition
15th Aug 20237:00 amRNSAcquisition
2nd Aug 20233:45 pmRNSDirector/PDMR Shareholding
1st Aug 202311:17 amRNSTotal Voting Rights
13th Jul 20234:20 pmRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSOutcome of audit tender process
11th Jul 20234:50 pmRNSDirector/PDMR Shareholding
6th Jul 202310:44 amRNSDirector/PDMR Shareholding
3rd Jul 20234:45 pmRNSTotal Voting Rights
29th Jun 20233:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.